News Releases

Approximately Half of the Planned Number of Subjects Have Received the First Dose, With No Reported Serious Adverse Events Study Progressing On Schedule Topline Results Expected Later This Year...

-- Current Drug Market Shortage Exists for Fludarabine Phosphate, An Injectable Chemotherapeutic Medication; Marketing Anticipated to Commence Later This Calendar Year -- PHILADELPHIA, May 12,...

Q3 Business and Financial Highlights: Net Sales were $78.4 Million Cash in Excess of $106 Million at March 31 Completed Sale of Liquid Manufacturing Plant for $10.5 Million; Major Elements of...

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2022 third quarter on Wednesday, May 4, 2022, after the market closes. Lannett management...

--First Patient Dosed, Topline Study Results Expected Later This Year; Potential BLA Filing in Early 2023 and Launch in the First Half of 2024-- TREVOSE, Pa., March 29, 2022 /PRNewswire/ --...

Lannett Company, Inc. (NYSE: LCI) today announced that it has received written notice from the New York Stock Exchange (NYSE) dated March 14, 2022, notifying the company that it is not in...

Lannett Company, Inc. (NYSE: LCI) today announced that the company will participate in a fireside chat at the 34th Annual ROTH Conference on March 14, 2022 at 12:30 p.m. PT at The Ritz Carlton, in...

Lannett Company, Inc. (NYSE: LCI) today announced that it has received written notice from the New York Stock Exchange (NYSE) dated March 2, 2022, notifying the company that it is not in...

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into material definitive agreements to sell its liquid drug manufacturing facility in Carmel, NY, as well as equipment located...

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2022 second quarter ended December 31, 2021. "For the quarter, ongoing and increasing competitive pricing pressure...

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2022 second quarter on Thursday, February 3, 2022, after the market closes. Lannett...

Lannett Company, Inc. (NYSE: LCI) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that they have completed the safety review of the Investigational New...

Lannett Company, Inc. (NYSE: LCI) today announced the submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the pivotal clinical trial of...

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2022 first quarter ended September 30, 2021. "For the quarter, solid sales of several key products contributed to...

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2022 first quarter on Wednesday, November 3, 2021, after the market closes. Lannett...

Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL, an internally developed product. Total U.S. sales of...

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2021 fourth quarter and full year ended June 30, 2021. "With the recently signed agreement to be the exclusive...

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2021 fourth quarter and full year on Wednesday, August 25, 2021, after the market closes....

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an exclusive U.S. commercialization agreement for a therapeutically equivalent generic of Spiriva® Handihaler®...

Lannett Company, Inc. (NYSE: LCI) today announced that it recently began marketing Fluvastatin Sodium Extended-release Tablets, 80 mg, a partnered product. Total U.S. sales of Fluvastatin Sodium...

Lannett Company, Inc. (NYSE: LCI) today announced the U.S. Food and Drug Administration (FDA) has accepted the Abbreviated New Drug Application (ANDA) for Fluticasone Propionate and Salmeterol...

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2021 third quarter ended March 31, 2021. "In recent months, we have significantly advanced a number of strategic...

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2021 third quarter on Wednesday, May 5, 2021, after the market closes. Lannett management...

Lannett Company, Inc. (NYSE: LCI) today announced the closing of the $350 million aggregate principal amount of 7.750% senior secured notes due 2026 (the "Notes") in a private placement to...

Lannett Company, Inc. (NYSE: LCI) (the "Company" or "Lannett") today announced the pricing of the $350 million aggregate principal amount of 7.75% senior secured notes due 2026 (the "Notes") in a...